UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 21, 2021
ORTHO CLINICAL DIAGNOSTICS HOLDINGS PLC
(Exact name of registrant as specified in charter)
| | | | |
England and Wales | | 001-39956 | | 98-1574150 |
(State or other jurisdiction of incorporation) | | (Commission File Number) | | (IRS Employer Identification No.) |
| |
1001 Route 202, Raritan, New Jersey | | 08869 |
(Address of principal executive offices) | | (Zip Code) |
Registrant’s telephone number, including area code: (908) 218-8000
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| | |
Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
Ordinary shares, $0.00001 par value | OCDX | Nasdaq Global Select Market |
US-DOCS\121128203.3
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
US-DOCS\121128203.3
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On May 19, 2021, Ortho Clinical Diagnostics Holdings plc (the “Company”) entered into a letter agreement with Michael Iskra, providing, subject to Mr. Iskra’s execution and nonrevocation of a separation agreement and release in a form satisfactory to the Company, for (i) minimum severance benefits equal to six (6) months’ continued base salary plus 50% of his target bonus and (ii) subsidized health benefit coverage during the six (6) month period following his termination, in each case, upon a termination of Mr. Iskra’s employment by the Company without cause (as such term is defined in the letter agreement).
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
US-DOCS\121128203.3
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Ortho Clinical Diagnostics Holdings plc
Date: May 25, 2021 | By:/s/ Joseph M. Busky |
| Title: | Chief Financial Officer |
US-DOCS\121128203.3
